Cardiff Lexington Corp (CDIX) stock

CDIXOTCServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 0/30

$0.04−0.01 (-25.53%)

Close on Oct 19, 2026Market cap $550.31KP/E –Yield –

Cardiff Lexington price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Cardiff Lexington's price to sales ratio was 0.1× on Oct 19, 2026, against 2.0× a year earlier. Over the last 5 years it ranged from 0.0× to 12.6×, with a median of 0.1×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Oct 19, 2026	0.1×	−3.1
2025	Dec 31, 2025	3.1×	−2.9
2024	Dec 31, 2024	6.0×	+6.0
2023	Dec 29, 2023	0.0×	+0.0
2022	Dec 30, 2022	0.0×	−0.0
2021	Dec 31, 2021	0.0×	+0.0
2020	Dec 31, 2020	0.0×	−2.1
2019	Jul 31, 2019	2.1×	–

Where these numbers come from

Parsed from the XBRL in Cardiff Lexington's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-3 reverse split on Jan 12, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CDIX.

Compare: CDIX vs BMGL · CDIX vs HLYK · CDIX vs SBC · CDIX vs EUDA · CDIX vs ALPS

Revenue growth-23.7% · median -26.8%

Operating margin-25.2% · median -65.1%

Net margin-126.4% · median -130.7%

Company	Revenue	Growth
SBC	$175.17M	-6.9%
CDIX	$9.07M	-23.7%
HLYK	$1.37M	-46.7%
BMGL	–	–
EUDA	–	–
ALPS	–	–

Company

Exchange: OTC
Industry: Services-Offices & Clinics of Doctors of Medicine
Fiscal year ends: December 31
Employees: 18
Auditor: GBQ Partners, LLC
SEC CIK: 811222

Advertisement
300 × 250

See a number that looks wrong?

Cardiff Lexington price to sales ratio

Price to Sales Ratio at the end of each year

More Cardiff Lexington figures